Abstract
In this issue of Blood, Shapiro et al report phase 2 results regarding daily concizumab prophylaxis in patients with hemophilia A or hemophilia B, thus providing proof-of-concept in preparation for the phase 3 clinical trial currently underway (NCT03741881).
Cite
CITATION STYLE
APA
Sidonio, R. F., & Zimowski, K. L. (2019). TFPI blockade: Removing coagulation’s brakes. Blood. American Society of Hematology. https://doi.org/10.1182/blood.2019002900
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free